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Substance use screeningBackground: The Affordable Care Act encourages healthcare systems to integrate behavioral and medical
healthcare, as well as to employ electronic health records (EHRs) for health information exchange and quality
improvement. Pragmatic research paradigms that employ EHRs in research are needed to produce clinical evi-
dence in real-world medical settings for informing learning healthcare systems. Adults with comorbid diabetes
and substance use disorders (SUDs) tend to use costly inpatient treatments; however, there is a lack of empirical
data on implementing behavioral healthcare to reduce health risk in adults with high-risk diabetes. Given the
complexity of high-risk patients'medical problems and the cost of conducting randomized trials, a feasibility pro-
ject is warranted to guide practical study designs.
Methods:We describe the study design, which explores the feasibility of implementing substance use Screening,
Brief Intervention, and Referral to Treatment (SBIRT) among adults with high-risk type 2 diabetes mellitus
(T2DM) within a home-based primary care setting. Our study includes the development of an integrated EHR
datamart to identify eligible patients and collect diabetes healthcare data, and the use of a geographic health in-
formation system to understand the social context in patients' communities. Analysis will examine recruitment,
proportion of patients receiving brief intervention and/or referrals, substance use, SUD treatment use, diabetes
outcomes, and retention.
Discussion: By capitalizing on an existing T2DMproject that uses home-based primary care, our study results will
provide timely clinical information to inform the designs and implementation of future SBIRT studies among
adults with multiple medical conditions.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Affordable Care Act encourages healthcare systems to integrate
behavioral and medical healthcare and use electronic health records
(EHRs) for health information exchange and quality improvementand Behavioral Sciences, Duke
. This is an open access article under[1,2]. Developing integrated systems in primary care to facilitate
management of substance use disorders (SUDs: tobacco, alcohol, or
drug) by using the EHR to streamline the workﬂow for substance use
Screening, Brief Intervention, and Referral to Treatment (SBIRT) has be-
come a priority [2,3]. SBIRT provides an ofﬁce-based framework that
may enhance the identiﬁcation of patients with substance misuse or
SUD and facilitate treatment and coordinated care [4,5]. In line with
the Triple-Aim reform, the United States (U.S.) is shifting away from
fee-for-service medical care to a value-based model that seeks notthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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value-based care system emphasizes the need to effectively identify
peoplewithmultiple comorbidities in order to engage them in a coordi-
nated chronic care model for outcome improvement [7–9]. For exam-
ple, the most costly 10% of the U.S. patient population (e.g., adults
with multiple chronic diagnoses such as diabetes and SUD) account
for 66% of total care expenditures [10]. Early detection of high-risk pa-
tients is necessary to implement targeted interventions thatwill reduce
avoidable hospitalizations and lower costs [9,10]. In keeping with the
value-based purchasing, home-based primary care is considered by
Institute of Medicine to be a promising care delivery model with long-
term cost-savings for those with complex health needs [7].
Diabetes is a leading cause of death and a commonly encountered
chronic disease in primary care [11,12]. As many as one in three U.S.
adults will have diabetes by 2050 [13]. About 90–95% of individuals
with diabetes have T2DM [14]. Diabetes is associated with severe, but
preventable, complications (e.g., limb amputations). Individuals with
diagnosed diabetes have medical expenditures estimated to be 2.3
times higher than those without diabetes [15]. Approximately 20% of
adults with diabetes are current cigarette smokers, and 50–60% are cur-
rent alcohol users [16]. Cigarette smoking, binge/heavy alcohol use, and
alcohol/drug use disorder interfere with diabetes self-care or increase
diabetes complications [17–20]. Diabetes complications and SUDs are
among the leading contributors to hospital admissions [21,22]. There-
fore, integrated care for diabetes and SUDs is critically needed to mini-
mize health risk. SBIRT should address all categories of SUDs.
There is a lack of data to inform implementation of SBIRT for adults
with T2DM. Recent data suggest that “brief intervention” is ineffective
among adult patients with severe drug use problems who have high
rates of poverty and/or psychiatric comorbidity [23,24]. Hence, an
SBIRT framework should take into account patients' substance use risk
level and incorporate referral to treatment to facilitate linkage to SUD
treatment. To inform the design of larger studies of an integrated
home-based practice model [7], we describe a prospective design to as-
sess the feasibility of implementing SBIRT among patients with high-
risk T2DM. This design considers substance use levels, includes referral
to SUD treatment, and leverages EHR in recruitment and data collection
to inform healthcare utilization.
2. Methods
2.1. Study aims
This National Drug Abuse Treatment Clinical Trials Network (CTN)
study assesses the feasibility of implementing SBIRT in patients with
high-risk T2DMwithin a home-based practicemodel, describes the sub-
stance use status of participating patients over time, and explores asso-
ciations between substance use and healthcare utilization.
2.2. Study area and setting
The diabetes epidemic is growing in North Carolina. In 1999, an esti-
mated 366,000 residents were livingwith diagnosed diabetes; ten years
later, the prevalence of diagnosed cases had increased to approximately
659,000 [25]. North Carolina is one of the southern states with the
highest prevalence (11.7%) of diagnosed diabetes in the nation [26,
27]. Compared with the overall U.S. population, Durham County has a
much higher proportion of Black/African American residents (13.2%
vs. 38.7%) [28]. Compared with Whites, Blacks/African Americans have
a higher prevalence of T2DM, poor quality of care, and diabetes related
complications and disability [29]. A multifactorial, community-based
approach has been recommended to improve patient outcomes via
targeting multiple diabetic risk factors [29]. We analyzed the EHR data
from over 170,000 adults aged ≥18 years in Durham County who re-
ceived care at one or more of the Duke University Health System clinics
during 2007–2011. We found that 17% of patients with T2DM had analcohol, tobacco, or drug use diagnosis documented in their EHR com-
pared with 8% of patients without T2DM [30]. Because SUDs have not
been systematically evaluated, the actual prevalence of SUD may be
higher than the documented prevalence.
The Duke University Health System serves as Durham County's pri-
mary hospital and emergency medicine system. The Durham Diabetes
Coalition (DDC) is part of the Southeastern Diabetes Initiative (SEDI;
Duke University IRB Pro00043463 funded by the Centers for Medicare
& Medicaid Services and the Bristol-Myers Squibb Foundation). The
DDCwas established in response to the escalating prevalence of disabil-
ity and death related to T2DM, particularly among racial/ethnic minor-
ities and adults of low socioeconomic status in Durham County [31].
The DDC is a joint effort of Duke University and external partners
(e.g., Durham County Department of Public Health, CAARE, Lincoln
Community Health Center). SEDI augments the existing standard of
care in an effort to improve population-level diabetes management,
reduce disparities in management and outcomes in underserved
communities, and lower healthcare costs for adults living with T2DM.
To contain study costs, our SBIRT study uses the existing SEDI infra-
structure to recruit patients who are SEDI participants in Durham
County.
2.3. Study designs
Our current study uses a prospective design, nestedwithin the larger
SEDI study, to explore the feasibility of implementing SBIRT among
adults with high-risk T2DM. We have employed the SEDI clinical team
to implement SBIRT in order to reduce costs and examine the feasibility
of conducting SBIRT in a real-world setting. Using EHR data, we identify
eligible patients for recruitment and prospectively track diabetes care
(medication adherence), health related quality of life, and healthcare
utilization (e.g., SUD treatment, emergency department or inpatient
hospitalization admissions). Our goal is not to test the efﬁcacy or effec-
tiveness of SBIRT, but to generate empirical data that will inform the
design, conduct, and implementation of EHR-enabled SBIRT among dia-
betes patients with multiple comorbidities within a chronic care model
[16,32]. Randomization and blinding are not part of the study design.
Speciﬁcally, due to a lack of substance use prevalence data in the
adult population with high-risk T2DM, we collect substance use
prevalence and severity data to guide the planning of future trials.
We collect recruitment, follow-up rates, as well as receipt of Brief In-
tervention (BI) and Referral to Treatment (RT) to understand the fea-
sibility of implementing SBIRT and to inform power analysis for
randomized trials. Additionally, we assess the diabetic medication
adherence prevalence, health related quality of life, emergency de-
partment encounters, inpatient admissions, and diabetes related
medical complications to explore their associations with substance
use. The latter information about substance use and diabetes related
healthcare utilization is relevant to informing the potential effect of
SBIRT on clinical practices and the designs of pragmatic randomized
trials.
2.4. SEDI inclusion and exclusion criteria
Our study includes eligible patientswith T2DMwhoare screened for
and identiﬁed as high-risk adults (described below) enrolled in the SEDI
home-based clinical intervention in Durham County, North Carolina
[31].
2.4.1. Inclusion criteria
To be included in the study, one must: 1) be ≥18 years; 2) have a
diagnosis of T2DM as deﬁned by one or more of the following: prior
diagnosis as designated by a clinician, glucose ≥126 mg/dl at fasting
and ≥200 mg/dl on random sample, or a glycated hemoglobin
(HbA1c) ≥6.5%; 3) be a resident of Durham County, North Carolina
or the neighboring areas, and receive the majority of their healthcare
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5) be deﬁned as high risk by the risk algorithm (detailed below); and
6) be referred from the primary care clinician or patient's medical
home.
2.4.2. Exclusion criteria
To be excluded from the study, one must: 1) lack the capacity to
make healthcare decisions and have no surrogate with the authority
to make these decisions for them; 2) have a terminal illness with a life
expectancy of 6 months or less; 3) have a diagnosis of type 1 or gesta-
tional diabetes; 4) be pregnant; or 5) be unwilling to comply with
study requirements. Because the screening and assessment tool for
SBIRT is only available in English, non-English speaking adults are also
excluded from the study. We will use the results from this study to
guide the study design for non-English speakers.
2.5. EHR data-drive approach to informing risk-stratiﬁed intervention
To inform targeted interventions and improve health outcomes for
patients with diabetes in Durham County, a mathematical risk algo-
rithmwas created using the EHR data fromDuke University Health Sys-
tem, including demographic, diagnoses, lab, and medication data and
was developed to assign adults with T2DM a risk score to place them
into low, moderate and high risk groups so that appropriate interven-
tions can be applied [31]. Speciﬁcally, a logistic regression equation
was developed using existing clinical data to predict risk for serious out-
comes, deﬁned as hospital/emergency department admission or death.Fig. 1. A conceptual model for an informatics-The initial algorithm predicted poor outcomes in calendar year 2011
based on 2010 EHR data, and then validated the model prediction
using 2012 EHR data. Candidate variables were selected from proven
risk factors for poor outcomes in patients with diabetes reported in
the literature and suggested by expert clinician input [31].2.5.1. An integrated EHR datamart
SEDI recruits patients either through direct referrals from providers
afﬁliated with the Duke University Health System or from screening the
Duke EHR system (with provider permission) to contact patients.
Potentially eligible patients are identiﬁed from the Duke EHR system
and referrals from providers afﬁliated with Duke University Health
System clinics. The primary source of EHR is the Duke Enterprise
Data Warehouse [33], which integrates EHR containing clinical data
(e.g., laboratory, diagnostics, clinical notes and tests) from clinical
encounters across the health system, including more than 25 major
clinical systems.
SEDI uses an EHR data-driven approach to informing risk-stratiﬁed
intervention. SEDI includes clinical sites located in four counties across
the southeastern United States: Cabarrus County, NC; Durham County,
NC;Mingo County,WV; and Quitman County,MS. To allow data sharing
for research analysis and progress reporting across data sharing part-
ners, an informatics team at DukeUniversity has developed an integrat-
ed EHR datamart. The conceptual model for this informatics- and
research-driven datamart is shown in Fig. 1 [34,35]. This datamart is de-
signed to accommodate project-speciﬁc research objectives and scope
by following a consistent set of practices, and integrated security is adriven electronic health record datamart.
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series of processes or components [34,35]: data sources (e.g., both inter-
nal and external data sources can be utilized independently for any
given project); project authorizations (contracting, authorizations, and
data use agreements are dependent on the context of each data source);
source system analysis (a methodical analysis of data and system archi-
tecture is applied for each individual data source with best practices of
proﬁling and metadata development); extract-transform-load processes
(these procedures programmatically mediate data transfers, data trans-
formations, identity matching, address standardization and geocoding,
and unstructured data); project-speciﬁc datamart (each datamart is
intended to be system agnostic to take advantage of rapidly-evolving
platforms, and it allows more agile adoption on an individual project
basis than a more centralized system would require); informatics
services and functionality (a catalog of services is incorporated to meet
each project's objective and scope); existing platforms (EHR-based plat-
forms provide a robust framework of functionality that can be deployed
as appropriate); consumers (themodel is intended to meet the needs of
project consumers with different roles and responsibilities); and inte-
grated security (security and patient conﬁdentiality are an integral part
of all systems and maintained through complimentary mechanisms
and policies).Fig. 2. An example of patient risk scorThis standardized EHR datamart permits regular data harvests from
multiple sources (EHR and non-EHR data sources), supports cross-site
data analysis, and facilitates the integration of patients' EHR data with
the census community-level information and patient-reported survey
data in the data analysis. For example, by combining a regular EHR
data extract with the risk algorithm, adults with T2DM can be
assigned a composite risk score that places them on the intervention
spectrum—from relatively low-risk, low-intensity, community-
based interventions to relatively high-risk, high-intensity, home-
based interventions [31]. To inform healthcare delivery and resource
allocation for Durham County residents with T2DM (e.g., pinpointing
the location of the neighborhood and community resources, linking
patients with resources convenient for them to access), geographic
information from the EHR is geocoded and linked with the census
block group-level information to provide a multidimensional under-
standing of environmental contexts and vulnerabilities for adults liv-
ing with T2DM in Durham and to develop tailored community-based
interventions. This geographic health information system (GHIS) ap-
proach integrates clinical, social, and environmental data to provide
tailored interventions that take into account a patient's neighbor-
hood and population-level factors [36]. Fig. 2 shows an example of
patient risk and community resource map [37]. Patient data wase and community resource map.
Table 2
Deﬁnition of SBIRT risk groups [41,42].
Risk group Deﬁnition
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tal factors to determine the high-risk neighborhoods for the neigh-
borhood interventions.The minimal risk S
group
Non-users of cigarettes, alcohol, and drugs.
The at-risk SBI
group
Current cigarette smokers, current alcohol users, or past-year
drug users (having DAST-10 scores 0–2 and all of the
following: no daily use of any illicit and nonmedical drugs, no
weekly use of illicit and nonmedical drugs, no injection drug
use for nonmedical reasons in the past 3 months, not in SUD
treatment)
The high-risk
SBIRT group
High-risk drinkers (AUDIT-C score ≥5) [45,46] or high-risk
drug users (having DAST-10 score ≥3, or having DAST-10
scores 0–2 and any of the following: daily use of any illicit or
nonmedical drugs, weekly use of illicit or nonmedical drugs,
injection drug use for nonmedical reasons in the past 3
months, currently in SUD treatment)2.5.2. SBIRT recruitment
The SBIRT study includes high-risk T2DM participants (risk score
within the top 10%) residing in Durham County targeted for enrollment
in SEDI. Potential SEDI participants who express an interest in partici-
pating in the SBIRT study go through the informed consent process at
the time they are consented for the SEDI study. They are then scheduled
for a home visit by trained research staff (socialworkers) to conduct the
SBIRT intake assessment. The SEDI clinical intervention also targets
those who have experienced barriers to effective management of
diabetes or roadblocks in accessing traditional ofﬁce-based primary
care (e.g., comorbidities, transportation barriers and lack of caregiver
support). This high-risk group receives home-based primary care deliv-
ered by a multidisciplinary team (nurse practitioner, social worker,
dietitian, and community health worker/patient navigator) over a peri-
od of up to 2 years; this home-based care is aimed at improving diabetic
care and outcomes [38–40]. Diabetic adults with comorbid conditions
have a high likelihood of frequently using inpatient or emergency
care, and inadequate access to care can exacerbate medical problems
[21,22]. Home-based primary care is considered in these high-risk
patients, since this care model combines traditional clinical care for
medical needs with team-based care management, self-care education,
and care coordination. Home-based primary care may reduce unneces-
sary hospitalizations and enhance coordination of social support ser-
vices and referrals to specialty clinics [38,39]. Consequently, the SBIRT
intervention is conducted in the participants' home.2.5.3. Sample size
Due to a lack of research data on engaging high-risk diabetes pa-
tients in SBIRT, our study is not powered to test the efﬁcacy of SBIRT.
Based on the projections for the SEDI clinical intervention,we plan to re-
cruit 120 patients over 16 months. To compensate participants for their
time, each participant is paid $25 for completing assessments at each
scheduled visit (baseline, four follow-up visits). Each participant may
receive up to $125 over the entire course of the study period.2.6. Data collection
2.6.1. The assessment battery (Table 1)
The assessment battery balances the need of brevity for screening
substance use against the costs of data collection in terms of staff time,
feasibility of completion in the primary care setting, and assessment re-
activity. The size of the assessment battery is minimized to contain the
cost and time of the study. The set of assessment for (nonmedical or
illicit) drug use is based on the NIDA CTN's common data elements for
SBIRT, including validated screening items and brief assessments toTable 1
A summary of substance use screening and assessments [41–43].
Smoking status Alcohol use status
Initial single-item use screen Do you currently smoke cigarettes? In the past month,
wine, or other alco
Problem use assessment Fagerstrom Test for Nicotine
Dependence (FTND) [44]
• Alcohol Use Diso
(AUDIT-C) [45,4
• Alcohol use diso
Note: SUD treatment use information are obtained from the EHR. In addition, self-reported tre
surveys.assess risk levels of substance use problems and intervention needs
[41,42].2.6.2. Deﬁnitions of SBIRT risk groups for intervention (Table 2)
Brief, single questions allow rapid identiﬁcation of substance use
[47]. After a positive screening, a brief assessment is performed to strat-
ify patients into three categories: minimal-risk, at-risk, and high-risk
substance use [41,42]. Since all participants are high-risk patients with
T2DM, identiﬁcation of at-risk and high-risk groups is critical to improv-
ing care coordination, especially for individuals manifesting medical
problems [4].2.6.3. Portable computer-assisted assessment tool
An electronic data capture (EDC) system is used to create computer-
assisted instruments. Due to the sensitive nature of substance use, the
use of portable computer-assisted methodology is considered to facili-
tate ease of access to the tool and provide the participantswith a private
means of responding to substance use questions. To enhance partici-
pants' reporting of substance use, questions are displayed on a portable
tablet screen, and the participant reads and enters responses directly
into the EDC system using the tablet. The substance use screening as-
sessment is conducted in a private setting. A touch screen tablet is
used to make the technology more user-friendly. Participants indicate
responses by simply touching the buttons on the screen.
Because high-risk patients with T2DM tend to be racial/ethnic
minorities or adults of low socioeconomic status, we collect patients' lit-
eracy level and implement a contingency plan. All participants take the
Rapid Estimates of Adult Literacy in Medicine Short-Form (REALM-SF)
[50]. To accommodate the patient's literacy level and preference, the re-
search staff may administer the assessment in a private setting and doc-
ument electronically the interviewmode and the patient's reason(s) for
not self-administering it to inform future study designs.Nonmedical or illicit drug use status
do you sometimes drink beer,
holic beverages?
How many times in the past year have you used an
illegal drug or used a prescription medication for
“non-medical reasons?” [47]
rders Identiﬁcation Test
6]
rder treatment status
• Drug Abuse Screening Test (DAST-10) [48,49]
• Drug type and frequency of use questions
• Injection drug use
• Drug use disorder treatment status
atment use for alcohol and drug use disorder that are related to SBIRT are collected from
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secure, web-based portal of the EDC system. The research staff and the
patient are required to log into the secure website with a username
and password. A separate username and password are generated for
the patient so that only the patient's record is visible. The patient can
only enter data into the currently open time-point to prevent incorrect
data entry. No data is stored on the portable tablets. Based on the
response patterns deﬁned by algorithms for the three intervention
groups, the EDC generates responses in the system to indicate the
patient's intervention status on the tablet (BI, RT, follow-up calls).
This portable tool accommodates home-based primary care and pro-
duces point-of-care triggers for the designed staff to provide the in-
tervention as indicated. Only designated research staff have access to
the information.
2.6.4. The SBIRT training and monitoring
Two trained research staff conduct SBIRT and follow-up calls. Re-
search staff complete two days of the SBIRT protocol and BI training
(e.g., substance use and diabetes, substance use in the Durham/North
Carolina area, SBIRT designs, substance use assessments, motivational
interviewing approach, SUD treatment options, and referral resources).
After completing the training, BI interventionists role-play with volun-
teers and then perform BI on at least two pilot patients with demon-
strated ﬁdelity evaluated by the BI trainer before conducting SBIRT.
The lead physician of the clinical team serves as an ongoing supervisor.
As a quality check, BI interventionists complete the BI checklist for each
BI to capture the BI content and action plan/progress; they also partici-
pate in bi-weeklymeetingswith the BI trainer to receive ongoing super-
vision and monitoring.
2.6.5. SBIRT intervention [4]
1. The minimal-risk S group is re-screened for substance use every 6
months, up to four times. Patients who screen positive for substance
use at any follow-up visit thenmove to the SBI or the SBIRT group, as
needed.
2. The at-risk SBI group is provided with a BI for reducing substance use
or misuse, and they are re-screened for substance use every 6
months, up to four times. Patients who use substances at follow-up
visits are provided with BI and/or RT, accordingly.
3. The high-risk SBIRT group is provided with a BI and RT at baseline.
Within the ﬁrst and second weeks of referral, the SBIRT group re-
ceives two phone calls to check on SUD treatment status and/or facil-
itate entry into SUD treatment.
This study includes one 20- to 30-minute BI session using Mo-
tivational Enhancement Therapy (MET) delivered during the
patient's visit to the diabetes clinic or home visit [4,51,52]. The
ﬁrst BI session focuses on establishing rapport, assessing patients'
substance use attitudes and use patterns, exploring coexisting is-
sues that may affect substance use behaviors and health conditions
(e.g., diabetes), assessing motivation to change substance use, pro-
viding feedback as needed, assessing readiness to change, and col-
laboratively negotiating goals and a plan of action. Subsequent BI
sessions are conducted on an individualized basis depending on results
from re-screening, as well as motivation and progress on behavior
change. Critical components include assessing and addressing barriers
to change, reviewing progress, providing feedback as needed, assessing
readiness, re-establishing a plan of action as indicated, and afﬁrming
positive behavior change. For cigarette and drug users, the interven-
tionist raises awareness as to the health and medical consequences of
any use. For alcohol use, this study follows the American Diabetes
Association's guidelines, which recommend that women have no
more than 1 alcoholic drink per day, and that men have no more than
2 alcoholic drinks per day (one drink is equal to a 12 oz beer, 5 oz
glass of wine, or 1 ½ oz distilled spirits) [53]. Lower (safer) limits ofalcohol use among older adults aged 65 and older are advised: “no
more than 1 standard drink” for elders [54].
The goal for RT is to incorporate SUD treatment into a standard
care setting for high-risk substance using diabetic patients. Given
that SBIRT services are new to this diabetic population, the interven-
tionist works with patients to help them better understand SUD
treatment. For patients who seem reluctant to pursue SUD treat-
ment, the interventionist informs them that SUD treatment begins
with a more thorough assessment of substance use and related prob-
lems before a treatment plan is prepared. The RT procedure includes
providing the patient with an information sheet listing treatment
programs (phone numbers, addresses) and SUD treatment service
resources in their community. Patients are asked about their willing-
ness to share the RT service information with their families or care-
takers. Patients who express an interest or willingness to use SUD
treatment are referred, as needed, by the study staff. Within the ﬁrst
two weeks of receiving the RT information, the SBIRT group receives
up to two phone calls to check on patients' intention and use of SUD
treatment services. The information collected during these phone calls
is recorded in the patient's EDC data.
2.6.6. Intervention discontinuation
BI is discontinued if the patient withdraws consent, or if there is
evidence that continuing in the study would be harmful to the
participant.
2.6.7. Follow-up
Follow-up assessments are conducted every 6months, up to 4 times,
unless a patient withdraws consent or there is evidence that continuing
in the study is harmful to the participant.
2.6.8. Substance use and clinical outcomes
The primary outcomes for substance use include changes in substance
use (cigarette, alcohol, or drugs), severity (FTND, AUDIT-C, and DAST
scores), and subsequent SUD treatment utilization. SUD-related medical
complications from the EHR are explored. Diabetes outcomes include:
medication adherence scores (collected by the parent study), healthcare
use (number of emergency department and inpatient encounters), and
diabetes-related complications (a summary of new diagnoses of medical
conditions, including kidney disease, peripheral neuropathy, retinopathy
or blindness, hypertension, heart failure, amputation, and stroke) from
the EHR. Health related quality of life data are assessed by the Patient Re-
ported Outcomes Measurement Information System (PROMIS) Global
Health Short Form to explore their changes over time and associations
with substance use and/or hospital admissions [55].
2.6.9. Stakeholder engagement
A Community Advisory Board (CAB) encompassingmultiple commu-
nity partners in Durham (e.g., non-proﬁt community-based organiza-
tions, health and medical centers, faith-based organizations, partners
serving people living with diabetes, community activists) has been con-
vened to provideprogramming, leadership, and support for different con-
stituencies impacted by diabetes. The study team (e.g., lead physician)
participates in the CAB meetings and discusses the status of SEDI/DDC
and SBIRT studies. In particular, the CAB members provide advice on is-
sues related to barriers to care (e.g., transportation, access to medication,
access to healthy food), community resources, study recruitment, and
retention.
2.7. Data analysis
Wewill examine the feasibility and implementation of SBIRT by pro-
ducing estimates of: recruitment time; demographic proﬁles to inform
recruitment strategies for future trials; extent of “intervention expo-
sure” (the extent to which planned interventions are delivered within
the speciﬁed timeframe); data completion (the extent of participants
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tools); retention (the extent to which participants remain in the study
and complete follow-ups; the extent to which the clinical intervention-
ists complete the planned brief intervention, referral to treatment ser-
vices, and follow-up calls); and the number of participants entering
SUD treatment.
We will conduct cross-sectional and longitudinal analyses to de-
termine prevalence and incidence of substance use, problem sub-
stance use, and SUD (including persistence and cessation in use).
The associations between SUD treatment use and substance use
will be explored.Wewill explore cross-sectional and longitudinal as-
sociations of substance use status (use, problem use, SUD, treatment)
with diabeticmedication adherence, health related quality of life, emer-
gency department/inpatient admissions, diabetes complications, and
psychiatric comorbidity.
Lastly, to provide a more complete picture of patients' intervention
needs and explore representativeness of the study sample, wewill com-
pare diabetes and substance use-related proﬁles of this sample with pa-
tients at the other three sites of SEDI that have not participated in the
SBIRT study, as well as patients in the Duke University Health System's
EHR data warehouse.
3. Discussion
An estimated 29.1million people or 9.3% of the U.S. population have
diabetes [12]. The total estimated cost of diagnosed diabetes was $245
billion in 2012, which reﬂects a 41% increase from a prior estimate in
2007. The largest components of medical expenditures are inpatient
care [15]. Adults who have diabetes with complications or SUD tend
to use more inpatient care than those without these diagnoses [21,22].
Cigarette smoking, heavy alcohol use, and alcohol/drug use disorder in-
crease the likelihood of medical complications [16]. Determining a fea-
sible means of incorporating SBIRT into diabetes care can help
minimize SUD-related consequences and reduce morbidity and costs.
The Substance Abuse and Mental Health Services Administration leads
efforts to advance the behavioral health of people in the U.S. and has is-
sued an advisory to encourage integrating diabetic care into behavioral
healthcare settings [8]. Yet empirical data are needed to guide integra-
tion of SBIRT into primary care settings that treat medical conditions
with high morbidity and mortality [56,57]. In line with the Institute of
Medicine's vision for pursuing pragmatic clinical research in real-life
settings to inform the development of learning healthcare systems
[58], our study is designed to provide such ﬁrst-hand clinical informa-
tion about feasibility and potential challenges in conducting SBIRT
among high-risk diabetic patients who have a pressing need for behav-
ioral health interventions and care coordination.
3.1. What this study adds to our knowledge
Due to healthcare reforms (Affordable Care Act, parity law), high-
quality integrated primary care (including home-based primary care)
is considered a key solution to improving care for individuals with
complex health conditions, including diabetes and SUDs [7,56–58].
SBIRT is considered a “primary care” approach to preventing substance-
related problems and enhancing early intervention and utilization of
evidence-based treatment; effective use of SBIRT may improve coordi-
nated specialty care for SUDs and tracking outcomes [4,8,57]. Neverthe-
less, empirical data from studies conducted in real-life settings are
needed to better understand the feasibility of implementing SBIRT and
its consequent clinical impact. Furthermore, EHR can be a crucial tool
not only for streamlining the SBIRT workﬂow through the use of EHR-
embedded decision algorithms, but for facilitating its implementation
through health information sharing and documentation of clinical quality
measures [1,2]. EHRdata also provide a practical research resource for de-
veloping learning healthcare systems [58]. These shifting changes in
healthcare delivery require the development of an innovative researchparadigm for behavioral healthcare and SUDs that is conducted in clinical
practices, taking into account patients' prior medical history and subse-
quent healthcare use and outcomes.
Our feasibility study is timely inmultiple ways. First, it is in linewith
national priorities geared towards identifyingways SBIRT can be incorpo-
rated into primary care, focusing on common and costly chronic condi-
tions (diabetes, SUDs) [5,8,59]. Second, since SBIRT among individuals
with complex health needs in primary care is an unexplored area of clin-
ical research, our study design represents a cost-effectiveway to leverage
the existing resources of a larger diabetes study and an EHRwarehousing
platform to explore the challenges of implementing SBIRT within a
chronic care framework. Third, the clinical data we obtain will be useful
for informing the design and conduct of practical SBIRT studies for
high-risk, high-cost patients with T2DM within a home-based primary
care model [7]. As noted by the Institute of Medicine report [7], research
is needed to inform home-based primary care models for improving the
growing number of high-risk or aging patients with complex health
needs. Finally, our study also will obtain valuable feasibility information
regarding the use of EHRdata to recruit eligible patients, the transmission
of patient care data to a common EHR datamart for data analysis, and the
use of ongoing treatment data for outcome evaluation.
3.2. Limitations and strengths
Due to cost considerations, this SBIRT project uses an observational
design and limits the scope of work to one study site; yet due to the
focus on feasibility-exploration, the use of one site allows targeting par-
ticipants for continuous follow-ups over a period of up to 2 years. The
longitudinal design, coupled with the use of EHR data for tracking clin-
ically important outcomes (e.g., diabetes related ED visits or inpatient
care) is the major strength of this study, given that this coupling will
provide information about recruitment, retention over time, and the im-
pact of an integrated intervention on clinically meaningful outcomes
available from EHRs. On the other hand, the ﬁndings from this study
conducted in a home-based primary care setting in Durham County
may not be generalizable to SBIRT delivered in traditional clinics or
other settings. Nonetheless, the Triple Aim reform incentivizes develop-
ments of team-based, chronic care models that will address behavioral
contributors (e.g., SUDs) to healthcare costs over time [3,6,7]. This
studywill make unique, timely contributions to the home-based prima-
ry care model, which is an emerging care delivery model that values
cost-saving and person-centered care for adults with complex chronic
illnesses [7]. Using an existing infrastructure from the larger SEDI
study also facilitates the feasibility study to explore the use of a common
EHR datamart for data collection and analysis. Given an increased em-
phasis on the importance of developing practice-based clinical trials,
we describe an example of interdisciplinary collaboration aimed at pro-
ducing clinical information to inform designs and implementation of in-
tegrated behavioral care and research efforts.
4. Summary
There is a clear need for developing integrated healthcare services to
identify and target modiﬁable behavioral health problems that contrib-
ute tomedical complications. The economic burden is expected to esca-
late as the prevalence of T2DM continues to rise, with costs being
predominately driven by adults with comorbid chronic diagnoses, in-
cluding SUD [60]. Integrated behavioral care has been understudied
among patients living with DM. Our feasibility study constitutes an ini-
tial, practical step to produce the necessary data to inform designs of
randomized SBIRT studies for understudied complex diabetic patients.
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